ELTX’s Phase 2 Trial Progress Outpaces Projections, Backed by Robust Immune Responses and Strengthened Cash Position
Key Clinical Update: Slower Than Expected Disease Progression Hints at Efficacy
Elicio Therapeutics is making noteworthy strides in its Phase 2 AMPLIFY-7P study evaluating ELI-002 7P for patients with pancreatic ductal adenocarcinoma (PDAC). As of November 2025, fewer disease progressions and deaths than originally forecasted have occurred in the trial. The company attributes this favorable trend to a possible impact on disease-free survival (DFS), though the trial remains blinded. Investors and clinicians now anticipate the event-driven DFS analysis in the first half of 2026—a critical milestone that could determine the future of this first-in-class immunotherapy for KRAS-mutant cancers.
Immunogenicity Data Signals Potential Broad Patient Benefit
Updated clinical results showcased at the Society for Immunotherapy of Cancer’s Annual Meeting revealed that ELI-002 7P triggered mutant KRAS (mKRAS)-specific T cell responses in 99% of evaluable patients. Of particular note:
- 86% overall antigen response rate
- 86.8% induced cytotoxic mKRAS-specific T cells
- 75% generated both CD8+ and CD4+ T cell responses
These responses spanned all seven mKRAS epitopes and were consistent across a range of human genetic backgrounds (HLA types). This suggests the potential for ELI-002 7P to benefit a genetically diverse, high-risk patient group—a key differentiator from more limited, personalized immunotherapy approaches.
Strong Cash Position Supports Clinical and Pipeline Expansion Into 2026
Since Q3 2025, Elicio has raised $11.1 million via its at-the-market program, extending its cash runway through the second quarter of 2026. As of September 30, 2025, cash and cash equivalents totaled $20.61 million, providing operational support through major clinical milestones ahead. The anticipated event-driven DFS analysis and a planned investigator-initiated Phase 1 trial at Memorial Sloan Kettering signal further clinical momentum into the next year.
| Key Financials (in $ thousands) | Q3 2025 | Q3 2024 |
|---|---|---|
| R&D Expense | 5,039 | 7,208 |
| G&A Expense | 3,006 | 3,136 |
| Total Operating Expenses | 8,045 | 10,344 |
| Net Loss | 10,083 | 18,838 |
| Net Loss Per Share | 0.60 | 1.39 |
| Cash and Equivalents (end of quarter) | 20,611 | 17,618 |
Clinical and Financial Foundations Set Stage for Pipeline Growth
Elicio is not only advancing ELI-002 7P in PDAC but also preparing for future studies in colorectal and potentially lung cancers. Recent discussions with the FDA have aligned both parties on the design of a future Phase 3 trial. Elicio’s amphiphile technology platform, which enhances the delivery and immune education at lymph nodes, remains a distinguishing feature of its approach—one aimed at maximizing both patient accessibility and therapeutic durability.
What to Watch: Key 2026 Catalysts
With the pivotal Phase 2 readout on the horizon, and cash reserves projected to last through this milestone, Elicio is positioned for a potentially transformative year. If the promising signals observed in early DFS data hold up, ELI-002 7P could advance rapidly towards Phase 3 and ultimately towards addressing the unmet needs of KRAS-mutant cancer patients. For now, all eyes will be on the first half of 2026 as the primary data matures.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI